Lucid Diagnostics (NASDAQ:LUCD) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Lucid Diagnostics from a “hold” to a “sell” rating, adding a bearish note to the stock’s recent analyst coverage.
• Despite that downgrade, the broader analyst view remains more positive: four analysts rate LUCD a Buy, one rates it a Sell, and MarketBeat shows a consensus “Moderate Buy” with a price target of $4.13.
• Lucid Diagnostics recently reported a quarterly loss of ($0.10) EPS, missing expectations, while shares traded near $1.03 with a market cap of about $201 million.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

LUCD has been the subject of several other reports. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $8.25 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, April 9th. Needham & Company LLC reiterated a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lucid Diagnostics in a report on Wednesday. Finally, BTIG Research reiterated a "buy" rating and issued a $2.50 price target on shares of Lucid Diagnostics in a report on Monday, March 30th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.13.

Lucid Diagnostics Price Performance

Shares of Lucid Diagnostics stock opened at $1.03 on Friday. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.70. The company has a market capitalization of $201.11 million, a P/E ratio of -1.07 and a beta of 1.10. The business has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.19.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $1.50 million during the quarter, compared to analysts' expectations of $1.39 million. As a group, research analysts expect that Lucid Diagnostics will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Centiva Capital LP acquired a new position in Lucid Diagnostics in the 3rd quarter valued at $25,000. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter worth $25,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics during the 1st quarter worth $39,000. SG Americas Securities LLC acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter worth $26,000. Finally, Abel Hall LLC acquired a new stake in shares of Lucid Diagnostics during the 4th quarter worth $33,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.